GSK · LONDON STOCK EXCHANGE ·
GSK plc
US FDA approves Hibsago for chronic hepatitis B
Our AI’s take
The announcement on 21 October 2026 confirms that the US FDA has approved GSK’s Hibsago (bepirovirsen) for chronic hepatitis B, a first‑in‑class antisense…
The full digestion is for members. What is good, what is bad and why, the numbers that matter, and the chart, then ask about it by voice or text.
Join freeNew to announcements? Learn what an RNS is and why prices move.